Acarix AB (publ) (STO:ACARIX)
Sweden · Delayed Price · Currency is SEK | Market Cap | 290.94M -27.8% |
| Revenue (ttm) | 9.22M +65.8% |
| Net Income | -39.38M |
| EPS | -0.04 |
| Shares Out | 1.19B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.2545 |
| Previous Close | 0.2580 |
| Day's Range | 0.2430 - 0.2545 |
| 52-Week Range | 0.2245 - 0.3900 |
| Beta | -0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Acarix AB
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden. [Read more]
Financial Performance
In 2025, Acarix AB's revenue was 7.36 million, an increase of 18.69% compared to the previous year's 6.20 million. Losses were -48.09 million, -27.34% less than in 2024.
Financial StatementsNews
Acarix AB Earnings Call Transcript: Q2 2026
Q2 2026 saw 102% revenue growth year-over-year, driven by U.S. expansion and new UAE regulatory approval. Gross margin remains strong at 80–90%, with operating expenses and net loss both reduced. Key milestones include CPT I transition progress and robust clinical validation.
Acarix AB Quarterly report: Q2 2026
Acarix AB has published its Q2 2026 quarterly earnings report on August 13, 2026.
Acarix AB Slides: Q2 2026
Acarix AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Acarix CADScor System Wins UAE Regulatory Approval For Coronary Disease Assessment
(RTTNews) - Acarix AB (ACARIX.ST), a Swedish medical device company, on Monday announced that its CADScor System has secured regulatory approval from the Emirates Drug Establishment (EDE) and the Mini...
Acarix Receives Regulatory Approval for the CADScor® System in the UAE (United Arab Emirates)
Approval opens market access across the UAE through commercial partner UniTech Solutions, bringing rapid, non-invasive coronary artery disease rule-out to point of care OKLAHOMA CITY, Aug. 10, 2026 /P...
Acarix AB Earnings Call Transcript: Q1 2026
Revenue rose over 40% year-over-year, led by 90% U.S. growth on a constant currency basis, while gross margin held at 81% and operating costs fell 32%. Regulatory and reimbursement progress, strong clinical results, and expanding primary care adoption support a positive outlook.
Acarix AB Quarterly report: Q1 2026
Acarix AB has published its Q1 2026 quarterly earnings report on May 18, 2026.
Acarix AB Slides: Q1 2026
Acarix AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 18, 2026.
Acarix AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 26% revenue growth, led by 87% U.S. market expansion and 64% increase in CADScor deliveries. Operating costs fell 23%, net loss improved 27%, and patch sales rose 73%. New payer and MDR certification support further global growth.
Acarix AB Quarterly report: Q4 2025
Acarix AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
Acarix AB Slides: Q4 2025
Acarix AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Acarix AB Annual report: Q4 2025
Acarix AB has published its Q4 2025 annual report on February 12, 2026.
Acarix AB Earnings Call Transcript: Q3 2025
Q3 saw 137% global revenue growth, 95% increase in system deployments, and 49% reduction in net loss, driven by MENA expansion and robust U.S. performance. Gross margin remained strong at 85%, with expanding reimbursement and new clinical milestones.
Acarix AB Quarterly report: Q3 2025
Acarix AB has published its Q3 2025 quarterly earnings report on November 6, 2025.
Acarix AB Slides: Q3 2025
Acarix AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
Acarix AB Earnings Call Transcript: Q2 2025
Q2 saw strong U.S. growth with a 27% increase in system deliveries and 53% patch sales growth in H1, while gross margin rose to 94% and operating costs fell 24%. Revenue declined due to European divestment, but new global distribution and reimbursement wins position the company for future profitability.
Acarix AB Quarterly report: Q2 2025
Acarix AB has published its Q2 2025 quarterly earnings report on August 21, 2025.
Acarix AB Slides: Q2 2025
Acarix AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 21, 2025.
Acarix AB (publ) publishes Interim Report, April - June 2024
NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the second quarter of 2024. The company achieved...
Acarix Shares Begin Trading on the US-based OTCQB Market
NEW YORK , July 15, 2024 /PRNewswire/ -- Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that the Acarix shares (OTCQB: ACIXF) begin trading today on the O...